Mobile App

Google Play Apple Store
A New Era in PAH: Reverse-remodeling Therapy – Advanced Clinical Cases
AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.

Pulmonary arterial hypertension (PAH) is a progressive and often fatal illness presenting with nonspecific symptoms of dyspnea, lower extremity edema, and exercise intolerance. Most of the available drugs and FDA‐approved therapies for treating pulmonary hypertension attempt to overcome the imbalance between vasoactive and vasodilator mediators and restore the endothelial cell function. New research has identified molecular targets that mediate vasodilation, anti‐inflammatory, and antifibrotic changes within the pulmonary vasculature. This on-demand presentation will provide an updated overview of new therapeutic approaches under investigation for the treatment of PAH, as well as strategies to optimize outcomes for patients with PAH.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.





Marc Humbert, MD, PhD Marc Humbert, MD, PhD
Professor of Respiratory Medicine
Paris-Saclay University
Director, French Reference Centre for Pulmonary Hypertension
Hospital Bicêtre
Vallerie McLaughlin, MD Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Professor of Internal Medicine
University of Michigan

20

Supported by an independent educational grant from
Merck Sharp & Dohme LLC a subsidiary of Merck & Co., Inc.


Launch Date: October 27, 2022

Release Date: October 11, 2022

Expiration Date: September 30, 2023

September 30, 2023
Mini Module
7484
TalkingPAH2022_WebBanner(1150px).gif
Pulmonology